Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-23-019884
Date:2023-03-15
Issuer: TARSUS PHARMACEUTICALS, INC. (TARS)
Original Submission Date:

Reporting Person:

WAHL BRYAN
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE, CA 92618

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2023-03-15 M 4,790 a $0.00 18,513 direct
COMMON STOCK 2023-03-16 S 337 d $13.43 18,176 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
RESTRICTED STOCK UNITS 0.0 2023-03-15 deemed execution date M 4,790 (d) common stock 4,790 $0.00 14,370 direct
Footnotes
IDfootnote
f1 the shares were issued pursuant to settlement of vested restricted stock units ("rsus").
f2 the sale reported on this form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of rsus. the sale is mandated by the issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.
f3 each rsu represents a contingent right to receive one share of the company's common stock.
f4 rsu granted on march 9, 2022, under the tarsus pharmaceuticals, inc. 2020 stock plan. 25% of the rsus will vest on march 15th of each of 2023, 2024, 2025, and 2026, subject to the reporting person's continuous service.
WhaleWisdom Logo

Elevate your investments